

Hyun Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8411999/publications.pdf>

Version: 2024-02-01

46
papers

1,904
citations

361296

20
h-index

276775

41
g-index

47
all docs

47
docs citations

47
times ranked

3215
citing authors

#	ARTICLE	IF	CITATIONS
1	A tripartite complex of suPAR, APOL1 risk variants and Î±vÎ²3 integrin on podocytes mediates chronic kidney disease. <i>Nature Medicine</i> , 2017, 23, 945-953.	15.2	176
2	Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. <i>Science</i> , 2021, 373, 931-936.	6.0	173
3	Severe Acute Respiratory Syndrome Coronavirus Papain-like Novel Protease Inhibitors: Design, Synthesis, Protein-Ligand X-ray Structure and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4968-4979.	2.9	129
4	Structure and Function of the Phosphothreonine-Specific FHA Domain. <i>Science Signaling</i> , 2008, 1, re12.	1.6	126
5	Inhibitor Recognition Specificity of MERS-CoV Papain-like Protease May Differ from That of SARS-CoV. <i>ACS Chemical Biology</i> , 2015, 10, 1456-1465.	1.6	114
6	Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. <i>Antiviral Research</i> , 2017, 139, 49-58.	1.9	113
7	Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2940-2955.	2.9	102
8	Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators. <i>European Journal of Medicinal Chemistry</i> , 2015, 103, 252-268.	2.6	88
9	Diphosphothreonine-Specific Interaction between an SQ/TQ Cluster and an FHA Domain in the Rad53-Dun1 Kinase Cascade. <i>Molecular Cell</i> , 2008, 30, 767-778.	4.5	74
10	Rufomycin Targets ClpC1 Proteolysis in <i>Mycobacterium tuberculosis</i> and <i>M. abscessus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	68
11	Airway Epithelial Cell-Derived Colony Stimulating Factor-1 Promotes Allergen Sensitization. <i>Immunity</i> , 2018, 49, 275-287.e5.	6.6	57
12	Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 167-177.	1.4	48
13	Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. <i>Cell and Bioscience</i> , 2021, 11, 45.	2.1	47
14	Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. <i>Antiviral Research</i> , 2021, 190, 105075.	1.9	44
15	Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 2722-2734.	2.5	41
16	High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads. <i>ACS Infectious Diseases</i> , 2019, 5, 829-840.	1.8	40
17	Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. , 2016, 57, 3313.		34
18	Reducing agents affect inhibitory activities of compounds: Results from multiple drug targets. <i>Analytical Biochemistry</i> , 2012, 423, 46-53.	1.1	31

#	ARTICLE	IF	CITATIONS
19	Antimycobacterial Rufomycin Analogues from <i>Streptomyces atratus</i> Strain MJM3502. <i>Journal of Natural Products</i> , 2020, 83, 657-667.	1.5	28
20	Insights into substrate promiscuity of human seryl-tRNA synthetase. <i>Rna</i> , 2017, 23, 1685-1699.	1.6	25
21	MMP14 Cleavage of VEGFR1 in the Cornea Leads to a VEGF-Trap Antiangiogenic Effect. , 2015, 56, 5450.		24
22	Hit-to-Lead: Hit Validation and Assessment. <i>Methods in Enzymology</i> , 2018, 610, 265-309.	0.4	23
23	Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1981-1989.	1.4	23
24	Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions. <i>Acta Crystallographica Section D: Structural Biology</i> , 2020, 76, 458-471.	1.1	23
25	High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes. <i>PLoS ONE</i> , 2013, 8, e75144.	1.1	21
26	Synergistic Inhibitor Binding to the Papain-Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications. <i>ChemMedChem</i> , 2013, 8, 1361-1372.	1.6	19
27	Nonimmune cell-derived ICOS ligand functions as a renoprotective α 2 β 3 integrin-selective antagonist. <i>Journal of Clinical Investigation</i> , 2019, 129, 1713-1726.	3.9	19
28	Ca-asp bound X-ray structure and inhibition of <i>Bacillus anthracis</i> dihydroorotase (DHOase). <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4536-4543.	1.4	18
29	High-level expression, purification, and characterization of <i>Staphylococcus aureus</i> dihydroorotase (PyrC) as a cleavable His-SUMO fusion. <i>Protein Expression and Purification</i> , 2013, 88, 98-106.	0.6	16
30	Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. <i>PLoS Pathogens</i> , 2021, 17, e1009312.	2.1	16
31	Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition. <i>Journal of Biological Chemistry</i> , 2020, 295, 15013-15028.	1.6	14
32	Over-expression, purification, and confirmation of <i>Bacillus anthracis</i> transcriptional regulator NprR. <i>Protein Expression and Purification</i> , 2016, 125, 83-89.	0.6	13
33	Identification of Non-Macrocyclic Small Molecule Inhibitors against the NS3/4A Serine Protease of Hepatitis C Virus through in Silico Screening. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 2245-2256.	2.5	12
34	Structural characterization of <i>Porphyromonas gingivalis</i> enoyl-ACP reductase II (FabK). <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2018, 74, 105-112.	0.4	11
35	Identification of potential binding sites for the FHA domain of human Chk2 by in vitro binding studies. <i>Biochemical and Biophysical Research Communications</i> , 2003, 311, 803-808.	1.0	10
36	Identification of Small Molecules Exhibiting Oxacillin Synergy through a Novel Assay for Inhibition of <i>vraTSR</i> Expression in Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	10

#	ARTICLE	IF	CITATIONS
37	Rufomycins or Ilamycins: Naming Clarifications and Definitive Structural Assignments. <i>Journal of Natural Products</i> , 2021, 84, 2644-2663.	1.5	10
38	Identification of <i>B. anthracis</i> N5-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 596-605.	1.4	7
39	Limonoids and other triterpenoids from <i>Entandrophragma angolense</i> . <i>FÃ-toterapÃ-Ãç</i> , 2021, 150, 104846.	1.1	7
40	MD simulations reveal alternate conformations of the oxyanion hole in the Zika virus NS2B/NS3 protease. <i>Proteins: Structure, Function and Bioinformatics</i> , 2020, 88, 345-354.	1.5	6
41	Histatinâ€1 is an endogenous ligand of the sigmaâ€2 receptor. <i>FEBS Journal</i> , 2021, 288, 6815-6827.	2.2	6
42	Identification of Small Molecule Inhibitors against <i>Staphylococcus aureus</i> Dihydroorotase via HTS. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9984.	1.8	6
43	A colorimetric assay optimization for high-throughput screening of dihydroorotase by detecting ureido groups. <i>Analytical Biochemistry</i> , 2013, 441, 87-94.	1.1	5
44	Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2349-2353.	1.0	4
45	Chemical constituents of <i>Entandrophragma angolense</i> and their anti-inflammatory activity. <i>Phytochemistry</i> , 2022, 201, 113276.	1.4	2
46	Discovery of small molecule inhibitors of adenovirus by disrupting E3-19K/HLA-A2 interactions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2837-2841.	1.0	0